Howard A. Burris, MD, also known as "Skip," of Sarah Cannon Research Institute, discussed how he wound up in the oncology space, his passion for getting to know and helping his patients, and some proud moments throughout his monumental career.
We had the pleasure of sitting down with Howard A. Burris, MD, also known as Skip, is the president of clinical operations and chief medical officer of Sarah Cannon Research Institute, as well as an associate of Tennessee Oncology. Not only is he a 2014 Giant of Cancer Care® in Drug Development, Dr Burris is also the elected president of ASCO for 2019 to 2020.
He has led a number of research endeavors and has been a part of the development of several agents now available for breast cancer treatment, such as ado-trastuzumab emtansine, everolimus, and gemcitabine.
In our exclusive interview, Dr. Burris spent time discussing how he wound up in the oncology space, his passion for getting to know and helping his patients, and some of his proudest moments throughout his monumental career, which includes his time as president of ASCO.